Trial reportBMC medicine2026
Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03015727 (Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Who cites it
2 citing papers in PubMed.
- Dietary preference, biological aging, and incident dementia: a prospective cohort study.GeroScience · 2026Article
- Combined multi-omics profiling and machine learning analysis reveals that Bregs and RPS2 promote bone metastasis in nasopharyngeal carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe present study sought to compare the clinical efficacy and safety profiles of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients who attained complete or partial response (CR/PR) following induction chemotherapy (IC).
methodsThis multicenter, randomized, open-label, phase 3 noninferiority trial was conducted at 7 Chinese hospitals. Patients with newly diagnosed stage III-IVb NPC who achieved CR/PR after IC were randomly allocated (1:1) to either the RT (IC + RT) group or the CCRT (IC + CCRT) group. The chemotherapy protocol was identical across the two treatment groups. The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall survival (OS) and the incidence of adverse events. Statistical analyses were performed using the Kaplan-Meier method and log-rank test.
resultsFrom December 2016 to May 2023, 220 eligible patients with histologically confirmed nasopharyngeal carcinoma were enrolled. The trial was terminated early due to slow accrual. Of these patients, 109 were assigned to the IC + RT group and 111 to the IC + CCRT group. The median follow-up was 57 months (range, 8-107 months). The IC + RT and IC + CCRT groups showed comparable 5-year progression-free survival rates (87.0% vs. 80.7%, P = 0.21). No significant differences were observed between the two treatment arms with respect to local relapse-free survival, regional relapse-free survival, locoregional relapse-free survival, distant metastasis-free survival, or overall survival (all P > 0.05). The IC + RT group had significantly lower incidences of grade 3-4 hematologic and gastrointestinal toxicities than the IC + CCRT group. Additionally, grade 1-2 deafness/otitis and liver dysfunction were also less frequent in the IC + RT group.
conclusionsIn NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT. Although the observed survival outcomes were numerically comparable, the premature termination of the trial and insufficient statistical power preclude a definitive noninferiority claim. These hypothesis-generating findings warrant validation in future adequately powered trials.
trial registrationClinicalTrials.gov, NCT03015727.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.